Chemex Pharmaceuticals announced Wednesday that it hasbegun clinical testing of TCV-309, a topical treatment forpsoriasis.

The Fort Lee, N.J. company (NASDAQ:CHMX) licenses TCV-309, aplatelet activating factor antagonist, from Takeda ChemicalIndustries Ltd. for dermatogical use. This product is beingdeveloped as part of a joint venture between Block Drug Co.Inc. and Chemex Pharmaceuticals Inc. Last December, Chemexfiled an investigational new drug (IND) application with FDA.

(c) 1997 American Health Consultants. All rights reserved.

No Comments